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Abstract
Background: Floating-Harbor syndrome (FHS) is a rare condition characterized by short stature, delays in expressive
language, and a distinctive facial appearance. Recently, heterozygous truncating mutations in SRCAP were
determined to be disease-causing. With the availability of a DNA based confirmatory test, we set forth to define the
clinical features of this syndrome.
Methods and results: Clinical information on fifty-two individuals with SRCAP mutations was collected using
standardized questionnaires. Twenty-four males and twenty-eight females were studied with ages ranging from 2
to 52 years. The facial phenotype and expressive language impairments were defining features within the group.
Height measurements were typically between minus two and minus four standard deviations, with occipitofrontal
circumferences usually within the average range. Thirty-three of the subjects (63%) had at least one major anomaly
requiring medical intervention. We did not observe any specific phenotype-genotype correlations.
Conclusions: This large cohort of individuals with molecularly confirmed FHS has allowed us to better delineate
the clinical features of this rare but classic genetic syndrome, thereby facilitating the development of management
protocols.
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Background
Floating-Harbor syndrome (FHS [MIM 136140]) is a
rare disorder characterized by short stature with delayed
bone age, deficits in expressive language and a distinct-
ive facial appearance. The name of the syndrome is
derived from the two hospitals where the first patients
were reported over 35 years ago [1,2]. Recently, we used
exome sequencing to investigate a cohort of 13 unrelated
individuals with classic features of FHS and identified
heterozygous mutations in SRCAP [MIM 611421] as
causative of this disorder [3]. All reported mutations were
truncating and occurred between codons 2,407 and 2,517
in exon 34 resulting in loss of three C-terminal AT-hook
motifs. SRCAP encodes a SNF2-related chromatin-remo-
deling ATPase that serves as a coactivator for CREB-
binding protein, better known as CBP, the major cause of
Rubinstein-Taybi syndrome (RTS). The disrupted inter-
action between these two proteins likely explains some of
the clinical overlap between FHS and RTS [4]. The
mechanism of disease in FHS is suspected to be
dominant-negative [3] due to the non-random clustering
of truncating mutations in the final exon that result in the
loss of the major transactivation function of SRCAP
located in a 655 residue C-terminal fragment, evidence
that expression of a construct solely consisting of the CBP
interaction domain of SRCAP strongly inhibits CREB-
mediated transactivation in a dominant-negative fashion
[5], and the existence of patients with haploinsufficiency
of SRCAP who do not have features of FHS [3].
Many of the features of FHS are non-specific (short
stature, delayed bone age, and language delays) and if
the distinctive facial features are not recognized, this
diagnosis can be difficult. Several years ago, Feingold [6]
provided a thirty-two year follow-up on the first reported
patient accompanied by a review of the literature. He
suggested that some of the patients reported to have FHS
did not fit the classical description and likely had a dif-
ferent condition. With the availability of a molecular test,
we are now able to further delineate the distinctive and
recognizable features of this syndrome.
Methods
Subjects and clinical data
Individuals with a presumptive clinical diagnosis of FHS
were invited to be part of this study. Clinical data was
collated from three sources: FORGE Canada Consortium
(Finding of Rare Disease Genes in Canada), based at the
Children’s Hospital of Eastern Ontario, the Manton
Center for Orphan Disease Research at Boston Children’s
Hospital, and the Radboud University Nijmegen Medical
Centre. All samples that were referred for analysis were
accepted for the study. Approval of the study design was
in compliance with the Helsinki Declaration and was
obtained from each of the participating institutions’
research boards. Free and informed consent was obtained
from each study subject (or guardian, if appropriate) prior
to enrollment. Recruitment e-mails were sent to all
members of the Floating-Harbor syndrome support group.
Interested families or physicians contacted the genetic
counselor at the Manton Center. A medical history
questionnaire was administered to the family or physician
via telephone, which reviewed all pertinent medical and
developmental history, as well as FHS-specific questions
(see Additional file 1). Referring providers who submitted
cases directly to the above institutions completed the
same questionnaire. In most cases, clinical photographs
were available prior to molecular testing and the likeli-
hood of finding a mutation was noted. Due to the diversity
of the sample sources, there was wide pre-test probability
of referred individuals actually having FHS, as this is a rare
condition and most clinicians do not have familiarity with
it. The clinical information from the first 13 subjects
described by Hood et al. [3] was also included.
Molecular analysis
Sanger sequencing of exons 31–34 of SRCAP was per-
formed using DNA samples from individuals with
suspected FHS (see Additional file 2). When available,
parental studies were performed to determine de novo
or inherited status. The clinical information, from
twenty-seven individuals who did not carry a mutation
in exons 31–34 of SRCAP, was used to help clarify key
diagnostic features. For three individuals, who most
closely resembled the FHS phenotype and for which no
mutations were identified in exon 34, complete sequen-
cing of the SRCAP gene was performed (primer sequences
available on request).
Results and discussion
Molecular
In total, 24 males and 28 females were identified with mu-
tations in SRCAP; 39 new individuals and 13 previously
reported [3]. Ages at time of data collection ranged from
two years to 52 years of age. The average age of diagnosis
was 8 years. Two mother/daughter pairs [7,8] and a
number of the other subjects have been previously
reported in the literature [1,3,6,7,9-11]. All the mutations
identified in our cohort were truncating (nonsense or
frameshift) alleles (Table 1). Two mutations are recurrent;
the Arg2444* mutation was observed in about half (24/52)
(including the original patient described by Pelletier and
Feingold [1]), while the Arg2435* mutation was present in
approximately one quarter (13/52) of the individuals with
FHS. In our original cohort of 13 patients with FHS we
delineated the boundaries of the critical region to between
codons 2407 and 2517. The extended cohort of
molecularly-defined patients we present here extends the
critical region to between codons 2389 and 2748, a further
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249 amino acids in exon 34. Interestingly, the boundaries
of this critical region are delineated by mutations observed
in our two mother-daughter pairs (Table 1), however, the
significance of this finding is unclear.
Facial gestalt
The face of FHS is the most distinctive aspect of this
syndrome (Figures 1, 2 and 3), and although there are
changes with age, the cardinal features, as originally
described [1,2,4], remain constant. The overall facial
shape is triangular. The nose is narrow at the root and
broadens to the tip. The columella is low hanging, nares
are large and the philtrum is often short. The upper
vermillion is typically thin and the lower lip is often
everted. The lips tend to be in a horizontal plane at rest
or when smiling. The eyes are frequently deep set and
the eyelashes tend to be long. The ears can be low set
and large in appearance. As seen in the photos, the FHS
phenotype is more difficult to recognize in infancy.
Skeletal
Of the 17 individuals where thumb morphology was
formally assessed, broad thumbs were only seen in 10
individuals indicating that they are a frequent but not
mandatory finding in FHS. The differential diagnosis of
broad thumbs includes Rubinstein-Taybi syndrome, where
they are a cardinal feature. FHS is also in the differential,
Table 1 Mutations detected in exon 34 of SRCAP in
individuals with FHS
c. DNA Frequency
(52)
Comments
Glu2389* c.7165G > T 2 Mother/Daughter [8]
Gln2407* c.7219C > T 1
Gln2407fs*35 c.7218_7219delTC 1
Asn2410fs*32 c.7230insA 1
Thr2425fs*17 c.7274insC 1
Arg2435* c.7303C > T 13 2nd Recurrent
mutation
Ala2440fs*3 c.7316dupC 1
Arg2444* c.7330C > T 24 Most frequent
Recurrent mutation
Pro2459fs*125 c.7374dupT 2
Pro2459fs*16 c.7376delC 1
Thr2512fs*5 c.7533_7534insAA 1
Gln2517fs*5 c.7549delC 1
Asn2618fs*11 c.7852insC 1
Arg2748* c.8242C > T 2 Mother/Daughter [7]
Figure 1 Facial photographs of 6 females with FHS with the common Arg2444* mutation.
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which is logical as SRCAP interacts with CBP. Other skel-
etal findings include broad first toes and brachydactyly.
Broad fingertips are seen frequently, and the fingers are
often described as being clubbed, although would be more
accurately classified as having broad fingertips (Figure 4).
Leisti et al. [2] reported a right-sided pseudoarthrosis-type
anomaly of the clavicle noted at age two in one of their pa-
tients. Four individuals in our series have uni- or bilateral
clavicular anomalies including pseudoarthroses or hypopla-
sia. Two individuals have 11 pairs of ribs and four have hip
dysplasia.
Growth
Where available, growth parameters were plotted on
aggregate graphs. Thirteen of 49 individuals had birth
weights less than the third percentile (Figure 5). For
females, the maximum height was at the 20th percentile,
with most data points between minus two and minus four
standard deviations (SDs) (Figure 6). For the males, the
height measurements varied more widely, with maximum
height at the 25th percentile and two adult heights below
four SDs (Figure 7). Occipito-frontal circumferences
(OFC) were more variable, with most being well within the
Figure 2 Facial photographs of 4 individuals with FHS of varying ages with the Arg2435* mutation.
Figure 3 Facial photographs of 7 individuals with FHS as examples of the other mutations. A. A female with the Gln2407* mutation.
B. A male with the Ala2440fs*3 mutation. C. A female with the Asn2618fs*11 mutation. D. A female and male with the Pro2459fs*125 mutation.
E. A mother and daughter with the Arg2748* mutation.
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average range (Figures 8 & 9). Seven individuals had OFCs
less than two standard deviations, and only one measure-
ment was less than minus 3 SDs. This suggests relative
sparing of head size in relation to stature. Body weights
were not consistent to suggest a particular body habitus
for this syndrome, and probably reflect the variability seen
in the general population.
Bone age and endocrine
Bone age values were plotted against chronological age
(Figure 10) and all values in subjects less than 8 years old
showed significant delays. There were no data values be-
tween ages 8–10 years, however, the bone ages approached
Figure 4 Hands and feet of individuals with FHS. Clinical photos demonstrating the variability of features ranging from unremarkable to
brachydactyly, short broad thumbs and big toes, broad fingertips.
Figure 5 Birth weights of individuals with FHS. Male birth
weights - blue dots; Female birth weights – pink dots. The mean,
5th and 95th confidence intervals are indicated.
Figure 6 Height and weight of female individuals with FHS.
Each point represents a single individual’s measurements at the time
of data collection.
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the chronological age or became advanced after age
10 years. A number of participants in this study have been
on growth hormone (GH) therapy, which may alter the nat-
ural history of growth in this population. Two of our sub-
jects have been assessed in more detail regarding this issue
[9,10]. Some GH treated individuals with FSH had docu-
mented GH deficiency, while others had modest responses
to treatment despite normal levels of GH [9,10,12]. Early
puberty has previously been reported [13] in FHS and was
documented in four individuals in our study. Some of our
subjects are currently pre-pubertal, while others could not
accurately report pubertal timing, rendering the data
incomplete. However, early puberty could explain the ad-
vanced bone age seen in teenage individuals with FHS as
well as contributing to shorter adult heights.
Structural anomalies
A number of structural anomalies were detected in our
cohort (Table 2), but no particular finding was seen with
enough frequency to consider it a distinguishing feature
of this syndrome. However, as some anomalies may
affect clinical management, comprehensive screening is
necessary in this population.
Voice quality and language
A high-pitched voice is often commented upon in in-
dividuals with FHS and was reported in 8/11 individ-
uals. Others noted a nasal quality to the voice. An
additional individual had documented velopharyngeal
Figure 7 Height and weight of male individuals with FHS. Each
point represents a single individual’s measurements at the time of
data collection.
Figure 8 OFCs of females with FHS. Each point represents a
single individual’s measurements at the time of data collection. The
mean, 5th and 95th confidence intervals are indicated.
Figure 9 OFCs of males with FHS. Each point represents a single
individual’s measurements at the time of data collection. The mean,
5th and 95th confidence intervals are indicated.
Figure 10 Bone age values plotted against chronological age
for 25 individuals with FHS.
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insufficiency (VPI), which may indicate that VPI is
under-recognized. Expressive language delay is a car-
dinal feature of this syndrome, and was reported in
all subjects. There was significant variability in sever-
ity with one individual who was bilingual, while an-
other could only speak a few words as an adult.
However, language development could potentially be
hampered by the high frequency of recurrent otitis
media and conductive hearing loss found in our
cohort.
Cognition
The cognitive abilities in individuals with FHS range
from average (IQ of 104) to significant intellectual
impairment in a few instances. Most individuals had
some modifications of their schooling (37/41). Obtaining
full psychoeducational assessments on this cohort was
beyond the scope of this study. However, when assessing
global cognition in an individual with FHS, one must
consider the language impairments, and in some ins-
tances sensory impairments, and adjust accordingly.
Behaviour
The caregivers, in comparison to physicians, who filled
out the questionnaires, often commented upon behavioral
issues for their children (5/25). It is likely that these issues
are under-recognized in this population. Rigid manne-
risms were observed (7/25), as were some obsessive
tendencies (e.g. skin picking). Parents often described
their children as anxious individuals and attention
deficit hyperactivity disorder (ADD or ADHD) was
common (9/32).
We acknowledge that the data collection in our study
was incomplete as data was obtained from a number of
sources without a centralized clinical assessment. We
also recognize that the ethnic backgrounds of the study
subjects were mostly Caucasian and that FHS may be
more difficult to diagnosis in other populations. How-
ever, three individuals of Chinese origin were clinically
diagnosed and identified to have mutations in SRCAP.
In addition to growth and developmental issues, all of
these subjects had classical FHS facial features, which
were distinct from those of their family members.
Lastly, we evaluated for the presence of a genotype-
phenotype correlation in FHS. Upon review of the clinical
data, no clinical features were identified which discriminated
between the different mutations. Given that all mutations
cause truncation in a very defined area of the gene, this
observation was not entirely unexpected.
Development of diagnostic criteria
The indication for analysis of the SRCAP gene was a pre-
sumptive diagnosis of FHS. The majority of those who
underwent testing had short stature, delayed bone age, lan-
guage delays and a distinctive facial appearance, usually
with a prominent nose. Clinicians very familiar with FHS
were able to distinguish those who ultimately carried a mu-
tation in SRCAP, by his/her clinical information and facial
photographs, from those who did not have a mutation.
Those individuals who were referred who did not have a
mutation detected often had dysmorphic facial features, but
these were distinct from the classical FHS gestalt, making
facial features the defining characteristic of FHS. The nose
is quite distinctive in FHS with its overall triangular appear-
ance, the orientation and size of the nares and the low
hanging columella. The linear orientation of the mouth, at
rest or when smiling, is also an important defining feature.
Additional consistent features of those who tested negative
were a formal diagnosis of autism or head circumferences
at a comparatively smaller OFC percentile than that for
height. Russell-Silver syndrome and 3-M syndrome are
Table 2 Frequency of different clinical features in
individuals with FHS
Clinical feature Frequency reported
Eyes
• Strabismus 7/43
• Hyperopia 5/43
• Nystagmus 1/43
Ears
• Recurrent otitis media/T-tube placement 6/52
• Hearing loss 9/52
• Cochlear anomaly 1/U
Other ENT
• Cleft lip and pseudocleft lip 2/52
• Velopharyngeal insufficiency 2/U
• Choanal atresia 1/U
Dental Issues
• Small teeth/increased spacing 13/38
• Cavities 6/38
• Malocclusion/underbite 3/38
Cardiac Malformation* 3/52
Gastrointestinal
• Motility issues (reflux/constipation) 13/52
• Colonic stricture 1/U
• Celiac disease 2/52
Genitourinary
• Cryptorchidism 5/24
• Renal/collecting system anomalies 7/U
Seizures 6/52
Hypothyroidism 2/52
U – denominator unknown.
* Mild aortic coarctation, atrial septal defect, Tetrology of Fallot.
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included in the differential diagnosis for FHS, but we do
not believe any of the patients in our negative group had
either of these diagnoses.
Three individuals, whose phenotype most closely
resembled FHS, had sequencing of the entire SRCAP gene
to explore the possibility of mutations outside of exons
31–34. However, no mutations were detected. It is plau-
sible that their phenotypes could be due to a mutation in
another gene that codes for a protein, which interacts with
SRCAP and CBP. Further research is needed to elucidate
this possibility. Given that we have no evidence of genetic
heterogeneity within our cohort, we conclude that the
detection of a truncating mutation in exon 34 of SRCAP is
a mandatory feature for a diagnosis of FHS. This is con-
trary to the report put forth by Le Goff et al. [14]. Six of
their nine subjects were found to have mutations in exon
34 within the boundaries we describe, and they proposed
that their three mutation-negative individuals indicate
genetic heterogeneity for FHS. However, we reviewed the
two photographs of their SRCAP-negative patients and
did not believe their facial features were consistent with a
diagnosis of FHS.
A high frequency of associated anomalies was seen in
this study (33/52 had at least one major anomaly requiring
medical intervention); however, none are pathognomonic
for FHS. This large cohort of FHS individuals clarifies
which clinical features are observed frequently and in-
forms patient management guideline development. For
example, celiac disease was initially thought to be more
common in FHS, however, only 2 of 52 subjects had this
finding. Although this is more than expected in compari-
son to the general population, the numbers are not such
to suggest generalized screening. In comparison, genito-
urinary, ocular and dental issues were seen often enough
to warrant investigations.
Suggestions for management
Based on our clinical data, we suggest the following
guidelines for the care of individuals with FHS:
1. Sequencing of SRCAP exons 31–34 in all suspected
cases to confirm the diagnosis
2. Complete assessments of auditory and visual systems
3. Renal and urinary tract ultrasound
4. Neurologic assessment if there is a suspicion of
seizures
5. Dental hygiene to prevent cavities and to monitor
for malocclusion
6. Evaluation for growth hormone deficiency at
baseline, to be repeated if loss of growth velocity
occurs
7. Monitoring of bone age and pubertal timing. In
cases of precocious puberty, referral to a pediatric
endocrinologist
8. Psychoeducational assessments corrected for
deficiencies in expressive language and sensory
issues
9. Monitoring of behavioral disturbances and provision
of early intervention
10.Counseling for families regarding recurrence risk
(extremely low) and to offspring of individuals with
FHS (50% chance).
Conclusions
We have assembled the largest cohort of individuals with
Floating-Harbor syndrome; documenting pathogenic muta-
tions in SRCAP in 52 affected individuals. Characteristic
clinical findings include short stature, delayed bone age,
distinctive facial features, expressive language delay, and
broad thumbs. If the characteristic facial gestalt is not
present, the likelihood of finding a mutation in SRCAP is
very low. It is not uncommon for an individual with FHS to
have additional anomalies and health complications that re-
quire medical intervention and thus comprehensive base-
line screening and surveillance is warranted. In general,
individuals with FHS are healthy and despite some impair-
ments, enjoy a good quality of life.
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